215 patents currently held
45 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
41
Ending by 2030
Nov 2026
Next term end
120
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2028 · High confidence
Also notable
Ends Jul 2029 · Medium confidence
Also notable
Ends Dec 2027 · High confidence
Devices, Systems and Methods for Treating Benign Prostatic Hyperplasia and Other Conditions
US 7,758,594
The most cited patent in this portfolio, cited by 1,638 later US patents, top 1% of utility patents granted in 2010 in our data. Protection runs to 2028.
Endovascular Devices and Methods of Use
US 9,339,207
Cited by 319 later US patents, top 1% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Devices and Methods for Crossing a Chronic Total Occlusion
US 7,763,012
Cited by 238 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Formerly held, still cited
Notable
Ends Oct 2029 · Medium confidence
Cited by 278 later US patents, top 1% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
now held by Teleflex Technologies LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 19 to 30, 2026 · next Nov 19
- 1 fee due Dec 13, 2026The maintenance fee for Expandable Tissue Engagement Apparatus and Method (US 11,672,520) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 3 fees due Jan 7 to 18, 2027 · next Jan 7
- 9 fees due Feb 1 to 27, 2027 · next Feb 1
- 3 fees due Mar 1 to 19, 2027 · next Mar 1
- 5 fees due Apr 10 to 30, 2027 · next Apr 10
- 2 fees due May 19 to 26, 2027 · next May 19
- 2 fees due Jun 1 to 8, 2027 · next Jun 1
- 1 fee due Aug 11, 2027The maintenance fee for Vascular Closure Device with Removable Guide Member (US 10,555,727) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 4 fees due Sep 10 to 26, 2027 · next Sep 10
- 1 fee due Oct 21, 2027The maintenance fee for Apparatus and Methods for Treating Obstructions Within Body Lumens (US 10,624,656) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
- 2 fees due Nov 5 to 10, 2027 · next Nov 5
Recent changes
- 4 of the patents on this record were granted since Aug 16, 2026
- 23 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 120 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Devices, Systems and Methods for Treating Benign Prostatic Hyperplasia and Other Conditions | 10 in force | to Oct 2031 |
| Pacing Guidewire | 6 in force | to Mar 2039 |
| Medical Device Position Location Systems, Devices and Methods | 5 in force | to Feb 2037 |
| Vascular Locating Systems and Methods of Use | 5 in force | to Mar 2035 |
| Hemostatic Devices | 5 in force | to Jun 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,668,705 | Latching Anchor Device In force · High confidence | In force | High confidence | |
| US 7,595,429 | Calcium Zeolite Hemostatic Agent held by Teleflex Life Sciences II LLC In force · Medium confidence | In force | Medium confidence | |
| US 8,252,344 | Partially Hydrated Hemostatic Agent held by Teleflex Life Sciences II LLC In force · Medium confidence | In force | Medium confidence | |
| US 7,968,114 | Clay-Based Hemostatic Agents and Devices for the Delivery Thereof held by Teleflex Life Sciences II LLC In force · High confidence | In force | High confidence | |
| US 8,007,503 | Apparatus and Method for Manipulating or Retracting Tissue and Anatomical Structure In force · High confidence | In force | High confidence | |
| US 7,594,509 | Heat and Moisture Exchange Device for Respiratory Therapy In force · High confidence | In force | High confidence | |
| US 12,076,448 | Hemostatic Devices held by Teleflex Life Sciences II LLC In force · Low confidence | In force | Low confidence | |
| US 8,252,318 | Devices and Methods for the Delivery of Blood Clotting Materials to Bleeding Wounds held by Teleflex Life Sciences II LLC In force · High confidence | In force | High confidence | |
| US 8,048,032 | Coaxial Guide Catheter for Interventional Cardiology Procedures In force · High confidence | In force | High confidence | |
| US 12,089,972 | Apparatus and Methods for Biopsy and Aspiration of Bone Marrow held by Teleflex Technologies LLC In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 215: 45 patents in force now held by others · 186 patents ended · 51 applications pending · 113 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.